Melinta Therapeutics, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.8M
Doctors Paid
17,089
Transactions
55,673
2024 Total
$976,592
Payment Breakdown by Category
Research$3.6M (40.6%)
Food & Beverage$1.4M (15.4%)
Consulting$1.0M (11.8%)
Travel$432,469 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 534 | 40.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 1,125 | 25.6% |
| Food and Beverage | $1.4M | 51,361 | 15.4% |
| Consulting Fee | $1.0M | 300 | 11.8% |
| Travel and Lodging | $432,469 | 1,917 | 4.9% |
| Education | $82,762 | 410 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $43,325 | 24 | 0.5% |
| Grant | $24,500 | 2 | 0.3% |
Payments by Type
General
$5.3M
55,139 transactions
Research
$3.6M
534 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ML-ORI-102 | $576,221 | 0 | 16 |
| A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin versus Standard of Care for the Treatment of Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infection | $341,173 | 1 | 53 |
| DEFINE-CABP | $292,748 | 0 | 76 |
| CEMPRA CE01-203 | $272,625 | 0 | 20 |
| An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (meropenem-vaborbactam) in Pediatric Subjects from Birth to Less Than 18 Years of Age with Serious Bacterial Infections | $158,032 | 1 | 38 |
| In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels | $150,000 | 0 | 2 |
| PEDVC | $119,109 | 0 | 9 |
| DCRI 6690 | $108,392 | 0 | 3 |
| An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections | $103,900 | 0 | 58 |
| An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS) | $92,946 | 1 | 53 |
| 02-PRJ69JS | $89,000 | 0 | 2 |
| CDS01 | $71,572 | 0 | 51 |
| ML-3341-119 | $70,523 | 0 | 1 |
| Stability of Meropenem and Vaborbactam at Room and Refigerated Temperatures in PCV IV infusion bags and Elastomeric Devices | $62,842 | 0 | 2 |
| Association between timing and choice of antimicrobial therapy for Stenotrophomonas maltophilia bloodstream infections in patients with hematologic malignancy | $62,660 | 0 | 3 |
| MDCO-MIN-16-05 | $60,582 | 0 | 6 |
| TMC-ORI-10-01 | $59,514 | 0 | 22 |
| Clinical and Economic Implications to the Hospital of Failure to Update Microbiology Breakpoints for Carbapenem-Resistant Enterobacteriaceae | $58,840 | 0 | 2 |
| In Vitro Activity of New Drug against Chlamydia Pneumoniae | $53,616 | 0 | 2 |
| Pharmacokinetics and Ex Vivo Sequestration of Rezafungin in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) | $50,000 | 0 | 1 |
| An Open-label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin Single-Dose Infusion in Pediatric Subjects less than 18 Years of Age with Suspected or Confirmed Bacterial Infections | $49,470 | 1 | 23 |
| Susceptibility to meropenem-vaborbactam and comparator agents in relation to clonal background among international carbapenem-resistant Escherichia coli clinical isolates | $48,213 | 0 | 2 |
| 306DH | $42,752 | 0 | 1 |
| The In-Vitro Activity of Delafloxacin and Comparator Agents Against Bacterial Pathogens Isolated from Patients with Cancer | $42,633 | 0 | 2 |
| Rempex 507 | $42,544 | 1 | 17 |
| Anchoring Intermittent long acting antimicrobials to medication for opiod use disorder treatment to facilitate structure transitions of care for people who use drugs admitted to the hospital with invasive infections (AIM-STOP) | $39,139 | 0 | 1 |
| Stability of Meropenem and Vaborbactam at Room and Refrigerated Temperatures in PVC IV Infusion Bags and Elastomeric Devices | $36,221 | 0 | 2 |
| Comparison of In vitro Susceptibility | $36,012 | 0 | 2 |
| CE06-302 | $33,364 | 0 | 22 |
| REMPEX 512 | $26,711 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Charles Sims, Md, MD | Infectious Disease | Shenandoah, TX | $37,934 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $36,726 | $0 |
| Fares Khater, Md, MD | Internal Medicine | Whitesburg, KY | $36,488 | $0 |
| Dr. Christian Sandrock, Md, MD | Internal Medicine | Sacramento, CA | $35,921 | $0 |
| David Robinson, M.d, M.D | Emergency Medicine | Houston, TX | $35,883 | $0 |
| Hector Brunet Rodriguez, Md, MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $35,151 | $0 |
| Dr. Brandon Smith, Md, Pharmd, MD, PHARMD | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $35,038 | $0 |
| Dr. Toral Patel, M.d, M.D | Internal Medicine | Chicago, IL | $34,440 | $0 |
| Dr. Ali Hassoun, Md, MD | Infectious Disease | Huntsville, AL | $33,093 | $0 |
| Christopher Cooper, Md, MD | Infectious Disease | Altamonte Springs, FL | $32,988 | $0 |
| Andrew Shorr, Md, MD | Pulmonary Disease | Washington, DC | $31,111 | $0 |
| Yoav Golan, M.d, M.D | Infectious Disease | Boston, MA | $29,461 | $0 |
| Dr. Luis Rosas, M.d, M.D | Internal Medicine | Mcallen, TX | $29,418 | $0 |
| George Sakoulas, Md, MD | Infectious Disease | San Diego, CA | $27,957 | $0 |
| Mujahed Abbas, M.d, M.D | Infectious Disease | Lansing, MI | $24,985 | $0 |
| James Mckinnell, M.d, M.D | Infectious Disease | Torrance, CA | $24,725 | $0 |
| Dr. Fredrick Melik-Abrahamian, D.o, D.O | Emergency Medicine | Sylmar, CA | $23,727 | $0 |
| Mark Pierce, Md, MD | Infectious Disease | Cookeville, TN | $22,020 | $0 |
| Dr. Alan Bulbin, M.d, M.D | Infectious Disease | Greenvale, NY | $21,654 | $0 |
| Brian Metzger, Md, MD | Infectious Disease | Austin, TX | $21,157 | $0 |
| Dr. Akshay Shah, M.d, M.D | Specialist | Bloomfield Hills, MI | $20,454 | $0 |
| Dr. Glenn Harnett, Md, MD | Emergency Medicine | Hoover, AL | $18,508 | $0 |
| Ahmad Ashfaq, M.d, M.D | Infectious Disease | Oklahoma City, OK | $18,218 | $0 |
| Michael Sore, M.d, M.D | Emergency Medicine | Tampa, FL | $18,146 | $0 |
| Hameed Ali, D. O, D. O | Internal Medicine | Temple, TX | $17,662 | $0 |
About Melinta Therapeutics, LLC
Melinta Therapeutics, LLC has made $8.8M in payments to 17,089 healthcare providers, recorded across 55,673 transactions in the CMS Open Payments database. In 2024, the company paid $976,592. The top product by payment volume is Baxdela ($2.2M).
Payments were distributed across 201 medical specialties. The top specialty by payment amount is Infectious Disease ($2.3M to 1,445 doctors).
Payment categories include: Food & Beverage ($1.4M), Consulting ($1.0M), Research ($3.6M), Travel & Lodging ($432,469).
Melinta Therapeutics, LLC is associated with 8 products in the CMS Open Payments database, including Baxdela, Vabomere, and Orbactiv.